Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
about
Sphingolipids: a potential molecular approach to treat allergic inflammationModulation of Autophagy by Sorafenib: Effects on Treatment ResponseEvolving concepts in cancer therapy through targeting sphingolipid metabolismCharacterization of isoenzyme-selective inhibitors of human sphingosine kinasesBiological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agentRecombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancerDrugging sphingosine kinases.Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells.Increased mRNA Levels of Sphingosine Kinases and S1P Lyase and Reduced Levels of S1P Were Observed in Hepatocellular Carcinoma in Association with Poorer Differentiation and Earlier Recurrence.Targeting sphingosine-1-phosphate in hematologic malignanciesIntracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesin phosphorylation and cancer cell invasion.The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma.Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.Evaluation of uttroside B, a saponin from Solanum nigrum Linn, as a promising chemotherapeutic agent against hepatocellular carcinomaTherapeutic potential of targeting sphingosine kinase 1 in prostate cancer.Oncogenic properties of sphingosine kinases in haematological malignancies.Major apoptotic mechanisms and genes involved in apoptosis.The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases.Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration.Targeting sphingosine-1-phosphate signaling for cancer therapy.Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity.Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.RNAi screen reveals a role of SPHK2 in dengue virus-mediated apoptosis in hepatic cell lines.The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer.Sphingolipid metabolism in cancer signalling and therapy.Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice.A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
P2860
Q21296721-AD94191E-80D4-4216-9CDD-E4C2FC0CABA5Q26745320-F4C80BDB-DDF7-440A-B2FD-2EF97522E657Q26863646-7AB45639-7CE5-4796-B368-044DE99C91E0Q28483643-00778206-4B43-4B6F-8BA2-DAB1362FE41FQ28486289-98E48213-D930-4321-9EA7-D9546E8F49EFQ28533335-244AF6BD-9763-4CE8-B501-AFE3EEBAEFE8Q30366282-A1C6695C-3714-46EF-8264-6488554C9A3BQ30408885-E6FFDA8C-F6CF-48BC-9D28-B1F7F6DA8D20Q30416881-D9099902-812E-4D49-8189-F52BEFAAA5ACQ34209320-E66E3031-00DE-4FCF-85E0-7332741E7855Q35204641-6765AE4D-82D7-4EEB-AC6D-23A611CD02D2Q35926140-37FEE858-9A67-479A-9FF2-1044598B8F4DQ36011176-863C952F-541D-47B3-8554-CEF0E7ED28C0Q36171317-FAB7775D-AED1-4630-994E-4E615F1AE995Q36359489-CDAED122-54D2-403A-96D3-2D25CD1C277CQ36868420-C887CE97-BFA7-4F02-964D-E82909694FA4Q37109693-0A2DE381-5D64-413C-91A6-77B73BC465CEQ37190258-38D2814F-7F4B-427E-9B49-284C7781CD63Q37390508-B74CA622-5D2E-4155-9E30-121221ADB39EQ37930972-323AEEB3-2B3E-4DD2-9281-5C319055F4CDQ38092176-910AF3DE-9F26-4705-A2A9-BD3C8E38329EQ38802454-68075B26-C83E-4750-A6D4-C835AEA623F2Q38909010-6AE21E4A-9E99-4998-BA22-80ECF1851C27Q38909416-CC92F700-AAEF-4791-9459-67B80EFD91D4Q38915115-4CE67128-4CCC-41D3-89C2-2A294B30F159Q39215469-75B1B8A1-5B13-461D-B962-A55C8ED92DFFQ39379449-1AE15F16-01FD-4914-8C5B-3EEA4759F3F9Q39496138-80FFD591-630E-4F37-AFC5-99ADB240EC41Q43203316-62EE918A-6D68-4A7D-90D9-E3F8F3A738B9Q45072762-67D5D19E-0C48-4BC1-A10F-45204B3452FCQ45324746-1600462D-BB59-45FD-8375-B5EEA482D9BCQ47130227-DD533BBF-D4B8-470B-B669-DBA413968346Q49950035-336D26B9-5B91-4446-99F4-7F53224B0592Q50021960-2E2AB442-9B40-4B3A-A116-60EAECC11612Q55001442-71F5552E-3DB2-4A44-B024-B3510C8750E2
P2860
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@ast
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@en
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@nl
type
label
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@ast
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@en
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@nl
prefLabel
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@ast
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@en
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@nl
P2093
P2860
P356
P1476
Antitumor activity of sphingos ...... cellular carcinoma xenografts.
@en
P2093
Charles D Smith
Clayton S Lewis
Vladimir Beljanski
P2860
P304
P356
10.4161/CBT.11.5.14677
P577
2011-03-01T00:00:00Z